Digital health

Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on:

Tuesday, January 30, 2024

CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah.

Key Points:

CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah.
John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

Cerus Corporation to Participate in Upcoming Investor Conferences

Retrieved on:

Thursday, February 1, 2024

Research, Medical Devices, Public Relations, Investor Relations, Communications, Health Technology, Health, General Health, Other Science, Science, CERS, Digital health, Corporation, Cerus Corporation, Conference

Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.

Key Points:

Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.
Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST.
A live webcast of the TD Cowen presentation will be available here and the replay will be available on the Company’s website after the event.

Register Now for the 2024 MedDev eMarketing Summit (San Diego, CA, United States - May 22-23, 2024) - ResearchAndMarkets.com

Retrieved on:

Thursday, February 1, 2024

Digital Marketing, Communications, Health, Medical Devices, Marketing, Summit, American frontier, Digital health, Environment, Authenticity, Power, Digital, Video game

The "2024 MedDev eMarketing Summit" conference has been added to ResearchAndMarkets.com's offering.

Key Points:

The "2024 MedDev eMarketing Summit" conference has been added to ResearchAndMarkets.com's offering.
Now in its 8th year, the popular MedDev eMarketing Summit is back next May 2024 in beautiful San Diego!
Advance your ENTIRE TEAM with up to two years' worth of new digital marketing strategies and expertise in just two days!
At MedDev 2024 we will be discussing:
Digital Health: Evolving from the Wild West to Established Medical Practice?

Cue Health to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on:

Wednesday, January 31, 2024

Health Technology, Health, Telemedicine, Virtual Medicine, Digital health, Conference

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024.

Key Points:

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024.

P3 Health Partners to Participate in The 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on:

Tuesday, January 30, 2024

General Health, Hospitals, Health, Practice Management, Managed Care, Digital health, PIII, Conference

P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.

Key Points:

P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Management is scheduled to host investor meetings on Tuesday, February 13th, and Wednesday February 14th, 2024.

Registration Now for the 2024 MedDev eMarketing Summit (San Diego, CA, United States - May 22-23, 2024)

Retrieved on:

Saturday, February 3, 2024

Marketing, Summit, American frontier, Digital health, Environment, Authenticity, Power, Digital

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- The "2024 MedDev eMarketing Summit" conference has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- The "2024 MedDev eMarketing Summit" conference has been added to ResearchAndMarkets.com's offering.
Now in its 8th year, the popular MedDev eMarketing Summit is back next May 2024 in beautiful San Diego!
Advance your ENTIRE TEAM with up to two years' worth of new digital marketing strategies and expertise in just two days!
At MedDev 2024 we will be discussing:
Digital Health: Evolving from the Wild West to Established Medical Practice?

Fordham University Gabelli School of Business Global Healthcare Innovation Management Center to Host – AI and Healthcare: Beyond the Hype

Retrieved on:

Wednesday, January 24, 2024

Pathology, Drink, Digital health, School, Statistics, Therapy, Health, Business school, Intelligence, AI, Wake Forest University, Drug discovery, Food, Gabelli School of Business, Hasso Plattner Institute, Master of Medicine, WFU, Management

The ultimate indicator of how successful AI will be in a healthcare setting hinges on synergizing technological innovation with institutional readiness that will ensure AI’s deployment in healthcare is both effective and transformative.

Key Points:

The ultimate indicator of how successful AI will be in a healthcare setting hinges on synergizing technological innovation with institutional readiness that will ensure AI’s deployment in healthcare is both effective and transformative.
The Fordham University Gabelli School of Business Global Healthcare Innovation Management Center (GHIMC) has invited thought leaders and innovators from academia, as well as those working in AI and the healthcare/pharmaceutical industries to examine the depth and complexity of the issues facing researchers, entrepreneurs, and executives at this critical juncture in the development of AI.
This in-person event will take place on February 1, 2024, 9:00am – 3:20pm on the 12th Floor of the Lowenstein Building, 113 W. 60 Street at Fordham University’s Lincoln Center campus.
The panels will be moderated by Falguni Sen, Ph.D., director of the Global Healthcare Innovation Management Center, and professor of Strategy and Statistics, Gabelli School of Business; and Navid Asgari, Ph.D., associate professor of Strategy and Statistics, Gabelli School of Business.

NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD

Retrieved on:

Thursday, January 18, 2024

LCD, Patient, ADHD, Food, Epilepsy, UCLA, Hospital, FDA, Digital health, Adolescence, Zorg, Monarch, Physician

LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder (ADHD).

Key Points:

LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder (ADHD).
The second-generation Monarch eTNS System (i.e., Monarch 2.0) is indicated for treatment of pediatric ADHD as a monotherapy for patients ages 7 through 12 years old who are not currently taking prescription ADHD medications.
Monarch 2.0 significantly improves upon the first-generation Monarch eTNS System.
“We believe that 2024 will be a transformative year for NeuroSigma,” said Dr. Colin Kealey, President and CEO of NeuroSigma.

SilverCloud by Amwell Earns Three International Awards

Retrieved on:

Thursday, January 18, 2024

Digital health, Patient, Research, Health care, Partnership, Anxiety, Public, Inter-State Bus Terminals, Organization, Most, Depression, Nursing

Boston, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, today announced that SilverCloud® by Amwell earned three international healthcare honors.

Key Points:

Boston, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, today announced that SilverCloud® by Amwell earned three international healthcare honors.
SilverCloud is a global digital mental health platform that provides 24/7 access to content and training for patients with mild to moderate symptoms of depression, anxiety and stress.
SilverCloud was honored at events celebrating excellence and achievement in digital health:
Winner of the Health-Tech Innovation of the Year at the Public Sector Digital Transformation Awards.
The award for the Most Transformative Impact – Digital Health at the National Health Tech Innovation Awards.

AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference

Retrieved on:

Thursday, January 25, 2024

Hospitals, Health, Cardiology, Medical Devices, LAA, Digital health, Atrial fibrillation, Conference

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.

Key Points:

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.
AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, February 15, 2024, to discuss its fourth quarter and full year 2023 financial results.
Those interested in listening to the conference call should register online using this link .
AtriCure’s management is also scheduled to host investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024, in Snowbird, Utah.